Skip to main content
XERAVA® (eravacycline) for injection homepage
XERAVA® (eravacycline) for injection homepage
Ordering Info

Access & Resources


Ordering Info

Contact a distributor

To order XERAVA, please contact one of the distributors below or download an Ordering Sheet.

If you would like more information about XERAVA or have questions related to research,
please contact
a Medical Science Liaison

Slide table to view more

NDC CodedistributorsContact Information
NDC 71773‑050‑1250 mg 12-vial carton containing 12 single‑dose vials.Cardinal Health Specialty Pharmaceutical Distribution1-866-677-4844
Morris & Dickson Co., L.L.C.1-800-388-3833
NDC 71773-100-12100 mg 12-vial carton containing 12 single‑dose vials (in shrink-wrap packaging).McKesson Specialty Health1-800-482-6700
McKesson Plasma
and Biologics
ASD Healthcare
Besse Medical1-513-851-2345


Download tools
for your
practice and patients



Download now
Patient Profile Joe

Patient Profile: Joe

Download now
Patient Profile Gloria

Patient Profile: Gloria

Download now
Dosing and Administration Guide

Dosing Guide

Download now
Ordering Sheet

Ordering Sheet

Download now

Want to
know more?

Request to speak with a
XERAVA sales representative
or receive information.

Lead the

Choose broad-spectrum
coverage for a broad range of
cIAI patients with XERAVA.1

Ordering info


  1. Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567-588. doi: 10.1007/s40265-016-0545-8.

Indications & Usage


XERAVA® (eravacycline) for injection is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.

Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).


To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Important Safety Information

XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs, or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.

The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis.

The most common adverse reactions observed in clinical trials (incidence ≥3%) were infusion site reactions (7.7%), nausea (6.5%), and vomiting (3.7%).

XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:

Innoviva Specialty Therapeutics, Inc.

U.S. Food and Drug Administration

Before administering, please see the Full Prescribing Information for XERAVA.

  • Prescribing Information
  • Important Safety Information
  • Ordering Info
  • MedWatch

XERAVA® is marketed by Innoviva Specialty Therapeutics, Inc. on behalf of Tetraphase Pharmaceuticals, Inc.

©2024 Innoviva Specialty
Therapeutics. All rights reserved. PM‑ERV‑00134‑US | 04/24

Innoviva Specialty Therapeutics™ Logo